Vraylar (cariprazine)

Vraylar (cariprazine) is a prescription second-generation antipsychotic (SGA). It is FDA-approved for schizophrenia, bipolar I disorder (including mania and depression), and as an adjunct medication for major depressive disorder (MDD) when used with an antidepressant.

Cariprazine is the medication’s generic (drug) name. Vraylar is the brand name.

Vraylar is an atypical antipsychotic, also known as a second-generation antipsychotic (SGA).

Vraylar affects dopamine and serotonin signaling in the brain. Like other SGAs, it is thought to help stabilize symptoms by changing how specific receptors respond to these neurotransmitters. Your clinician can explain how that mechanism relates to your symptoms and diagnosis.

Vraylar is used to treat schizophrenia and bipolar I disorder (including manic, mixed, and depressive episodes). It is also used as an add-on treatment for major depressive disorder (MDD) alongside an antidepressant.

Vraylar is not FDA-approved for anxiety disorders. If anxiety symptoms are part of your clinical picture, your provider can discuss evidence-based options and whether Vraylar fits the overall treatment plan.

Some people notice early changes within the first couple of weeks, but meaningful symptom improvement can take several weeks. Response varies by diagnosis, symptom severity, and dose adjustments.

Commonly reported side effects include restlessness (akathisia), sleepiness or insomnia, nausea, dizziness, and appetite changes. Side effects vary by individual and dose.

Weight gain is possible with Vraylar. In clinical trials, some individuals experienced modest weight increases compared with placebo. Individual responses vary, and not everyone will gain weight. You and your clinician should monitor weight regularly during treatment and discuss any concerns as part of ongoing care.

Yes, Vraylar (cariprazine) can cause sleepiness, drowsiness, and fatigue as a common side effect. While it is not designed specifically for sedation, clinical studies showed about 6% to 7% of individuals reported feeling sleepy, which may impair the ability to drive or operate machinery. It may also cause dizziness, restlessness, and slow movements.

Seek urgent medical care for severe restlessness, fainting, high fever, muscle rigidity, confusion, uncontrolled movements, allergic reactions, or worsening suicidal thoughts.

Yes. Akathisia, or inner restlessness, is a known potential side effect. If this occurs, contact your prescriber rather than stopping medication on your own.

No. Vraylar is not classified as a controlled substance.

Try to avoid alcohol while on Vraylar. Combining alcohol with Vraylar can significantly increase side effects like extreme drowsiness, dizziness, confusion, and impaired motor coordination. It may also reduce the effectiveness of the medication in treating your condition.

Always follow your psychiatric provider’s directions on when to stop taking medications or change dosages. Abrupt discontinuation may lead to symptom recurrence or uncomfortable effects.

Some people experience symptom rebound or physical discomfort when stopping or changing psychiatric medications. A clinician-guided plan helps minimize risk. Always follow your psychiatric provider’s directions on when to stop taking medications or change dosages.

Vraylar is FDA-approved as an adjunct treatment for depression, meaning it can help depression when taken with an antidepressant. Consult your prescribing clinician before starting, stopping, or combining any medications or substances with Vraylar (cariprazine).

Vraylar (cariprazine) has significant interactions with CYP3A4 inhibitors (increasing side effects) and inducers (reducing effectiveness), as well as CNS depressants. Major interactions include antifungal agents (ketoconazole), antibiotics (rifampin), seizure medications (carbamazepine, phenytoin), St. John’s wort, and antidepressants.

Vraylar (cariprazine) and Abilify (aripiprazole) are both atypical antipsychotics used for schizophrenia and bipolar disorder.

Key differences between Vraylar and Abilify:

• Uses: Both treat schizophrenia and bipolar I disorder (mania/mixed). Vraylar is also approved for bipolar depression, but Abilify is not. Abilify is approved for pediatric autism-related irritability and Tourette syndrome.
• Side effects: Vraylar is less likely to cause significant weight gain compared to many other antipsychotics, including Abilify. Both can cause restlessness, nausea, and movement disorders.
• Administration: Abilify is available as oral tablets, solution, and long-acting injections. Vraylar is only available as an oral capsule
• How they work: Vraylar has a stronger affinity for certain dopamine (D3) receptors, which may provide better results for the negative symptoms of schizophrenia, such as a lack of motivation.

Vraylar (cariprazine) and Latuda (lurasidone) are both atypical antipsychotics used for schizophrenia and bipolar depression, but differ in key areas: Vraylar is approved for a broader range of bipolar symptoms (mania/mixed episodes) and as an add-on for major depressive disorder (MDD). Latuda requires administration with a 350-calorie meal, while Vraylar does not.

Key differences between Vraylar and Latuda:

• Indications: Both treat schizophrenia and bipolar I depression. Vraylar is also FDA-approved for bipolar I mania and as an add-on treatment for MDD in adults.
• Administration: Latuda must be taken with at least 350 calories of food, which is crucial for absorption. Vraylar can be taken with or without food.
• Side effects: Vraylar is more associated with movement issues (akathisia/restlessness) and, though both can cause weight gain, it is less common with Vraylar than with some other antipsychotics. Latuda is known to cause sleepiness and nausea.

Vraylar (cariprazine) and Rexulti (brexpiprazole) are both brand-name, daily oral atypical antipsychotics used for schizophrenia and add-on depression treatment, but they differ in approved uses, side effects, and mechanism. Vraylar treats bipolar I disorder, while Rexulti treats Alzheimer’s-related agitation. Vraylar is associated with higher risks of restlessness/movement issues, whereas Rexulti is more likely to cause moderate weight gain.

• • Approved Indications:
    • Vraylar: Approved for schizophrenia, manic, mixed and depressive episodes associated with Bipolar I disorder, and for adjunctive treatment of major depressive disorder (MDD)
    • Rexulti: Approved for schizophrenia, adjunctive treatment for major depressive disorder (MDD) and PTSD, and agitation associated with dementia due to Alzheimer’s disease.
  • Side Effect Profiles:
    • Vraylar: Common side effects include restlessness (akathisia), movement issues (extrapyramidal symptoms), nausea, and insomnia. It is generally considered weight-neutral or to cause less weight gain compared to other antipsychotics.
    • Rexulti: Common side effects include weight gain, increased appetite, fatigue, and headache.

Cariprazine is the generic name for Vraylar. Generic availability depends on current market approvals and pharmacy supply.

The cost of Vraylar varies by dose, quantity, pharmacy, and insurance coverage. As of publication date, Vraylar oral capsules are listed at approximately:

• 1.5 mg: from $1,046.45 for 20 capsules
• 3 mg: from $1,046.45 for 20 capsules
• 4.5 mg: from $1,565.72 for 30 capsules
• 6 mg: from $1,565.72 for 30 capsules

If you have insurance, your out-of-pocket cost will depend on your supporting diagnosis and plan type (e.g., commercial, Medicare, Medicaid) and may include a copay or coinsurance.

Clinically, Vraylar is classified as a second-generation antipsychotic. It is FDA-approved for bipolar I disorder and may function as part of a broader mood-stabilizing treatment plan.